BTIG Downgrades DermTech Inc. (DMTK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Lake Street Capital Markets Downgrades DermTech Inc. (DMTK) to Hold
April 19, 2024 7:29 AM EDTLake Street Capital Markets analyst Thomas Flaten downgraded DermTech Inc. (NASDAQ: DMTK) from Buy to Hold with a price target of $0.63.
For an analyst ratings summary and ratings history on DermTech Inc. click here. For more ratings news on DermTech Inc. click here.
Shares of DermTech Inc. closed at $0.59 yesterday.
... MoreDermTech (DMTK) to Explore Strategic Alternatives and Implement Restructuring Plan
April 18, 2024 4:16 PM EDTDermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger,... More
